These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Biological treatments for severe asthma: A major advance in asthma care. Busse WW Allergol Int; 2019 Apr; 68(2):158-166. PubMed ID: 30792118 [TBL] [Abstract][Full Text] [Related]
6. The potential of biologics for the treatment of asthma. Pelaia G; Vatrella A; Maselli R Nat Rev Drug Discov; 2012 Dec; 11(12):958-72. PubMed ID: 23197041 [TBL] [Abstract][Full Text] [Related]
7. An update on biologic-based therapy in asthma. Walsh GM Immunotherapy; 2013 Nov; 5(11):1255-64. PubMed ID: 24188679 [TBL] [Abstract][Full Text] [Related]
8. The use of biologic therapies for the management of pediatric asthma. Lovinsky-Desir S Pediatr Pulmonol; 2020 Mar; 55(3):803-808. PubMed ID: 31880870 [TBL] [Abstract][Full Text] [Related]
9. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma. Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951 [TBL] [Abstract][Full Text] [Related]
10. Role of Biologics in Asthma. McGregor MC; Krings JG; Nair P; Castro M Am J Respir Crit Care Med; 2019 Feb; 199(4):433-445. PubMed ID: 30525902 [TBL] [Abstract][Full Text] [Related]
11. Biologics for Severe Asthma: Treatment-Specific Effects Are Important in Choosing a Specific Agent. Krings JG; McGregor MC; Bacharier LB; Castro M J Allergy Clin Immunol Pract; 2019; 7(5):1379-1392. PubMed ID: 31076056 [TBL] [Abstract][Full Text] [Related]
12. Recent developments in the use of biologics targeting IL-5, IL-4, or IL-13 in severe refractory asthma. Walsh GM Expert Rev Respir Med; 2018 Nov; 12(11):957-963. PubMed ID: 30193532 [TBL] [Abstract][Full Text] [Related]
13. Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma. Arron JR; Choy DF; Scheerens H; Matthews JG Ann Am Thorac Soc; 2013 Dec; 10 Suppl():S206-13. PubMed ID: 24313774 [TBL] [Abstract][Full Text] [Related]
14. [Treatment of refractory asthma with antibodies]. Lommatzsch M Dtsch Med Wochenschr; 2016 Jun; 141(11):790-3. PubMed ID: 27254629 [TBL] [Abstract][Full Text] [Related]
15. Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies. Chung KF J Intern Med; 2016 Feb; 279(2):192-204. PubMed ID: 26076339 [TBL] [Abstract][Full Text] [Related]
16. Omalizumab attenuates airway inflammation and interleukin-5 production by mononuclear cells in patients with severe allergic asthma. Takaku Y; Soma T; Nishihara F; Nakagome K; Kobayashi T; Hagiwara K; Kanazawa M; Nagata M Int Arch Allergy Immunol; 2013; 161 Suppl 2():107-17. PubMed ID: 23711861 [TBL] [Abstract][Full Text] [Related]
17. Biologic and New Therapies in Asthma. Tabatabaian F; Ledford DK; Casale TB Immunol Allergy Clin North Am; 2017 May; 37(2):329-343. PubMed ID: 28366480 [TBL] [Abstract][Full Text] [Related]
18. Selecting the right biologic for your patients with severe asthma. Manka LA; Wechsler ME Ann Allergy Asthma Immunol; 2018 Oct; 121(4):406-413. PubMed ID: 30056149 [TBL] [Abstract][Full Text] [Related]
19. The effect of omalizumab on eosinophilic inflammation of the respiratory tract in patients with allergic asthma. Kupryś-Lipińska I; Molińska K; Kuna P Pneumonol Alergol Pol; 2016; 84(4):232-43. PubMed ID: 27435350 [TBL] [Abstract][Full Text] [Related]
20. Biologics for paediatric severe asthma: trick or TREAT? Saglani S; Bush A; Carroll W; Cunningham S; Fleming L; Gaillard E; Gupta A; Murray C; Nagakumar P; Paton J; Roberts G; Seddon P; Sinha I Lancet Respir Med; 2019 Apr; 7(4):294-296. PubMed ID: 30824361 [No Abstract] [Full Text] [Related] [Next] [New Search]